Introduction
The lentiviral vector is a powerful tool for transduction of genes into many cell types, especially non-dividing cells such as neurons, and is being used in clinical trials of human gene therapies and other applications. [1] [2] [3] [4] [5] [6] [7] [8] The use of lentiviral vectors has been made possible because of advances in basic virology and because of a series of modifications that have increased the safety of the lentiviral vector. The commonly used third-generation lentiviral vector is a Tat-independent four-plasmid system composed of a gene transfer vector and three trans-vectors expressing Rev, Env and Gag-pol. The gene transfer vector is equipped with a self-inactivation LTR system (SIN). Viruses are often pseudotyped by vesicular stomatitis virus G (VSV-G). The human codon-optimized gag-pol expression vector is used to increase viral yield. 9 The application of the lentiviral vector to human gene therapy was first approved for the treatment of human immunodeficiency virus (HIV) infections in the early 2000s. 1 . Since then, because of its potential advantages, the use of lentiviral vector has been expanding. A large amount of lentiviral particle must be produced for clinical trials. A technical improvement to increase the viral titer obtained from a production system would have a substantial effect on the cost of supporting a clinical human gene therapy trial using the lentiviral vector. The lentiviral vector titer in current production systems is generally in the order of 10 5 -10 6 transducing units per ml. Although titer can be increased by centrifugation, the production yield is not as high as other viral vectors including the widely used adenoviral vectors. The HIV-1-based lentiviral vector has been engineered to reduce the risk of pathogenicity associated with HIV-1 5, 9 , which resulted in a decrease of the viral titer.
Retroviral production and infectivity are regulated by the amino-terminal matrix domain (p17 MA or MA) of Pr55
Gag (Gag). [10] [11] [12] [13] The myristoylation (myr) signal in the MA is critical for efficient viral production by aiding Gag trafficking to the plasma membrane (PM). In a previous study, we found that substitution of the HIV-1 Gag myr with the phospholipase C-d1 pleckstrin homology (PH) domain increased the production of the third-generation lentiviral vector in which the gag-pol is human codonoptimized. 14 This prompted us to search for a PMtargeting signal that could enhance viral production to a greater extent than PH-Gag. Among the PM-targeting signals, we discovered that the myr signal motifs of several heterologous proteins conferred such an effect. We suggest that the resulting modified Gag-based lentiviral vector can serve as a next generation lentiviral vector system, and should contribute to diverse applications of the lentiviral vector.
Results
We constructed HIV-1 Gag constructs (Figure 1a ) containing the following PM-targeting proteins or PMtargeting signals fused to the Gag amino-terminus: the transmembrane proteins CD4, CD8, CXCR4, HIV-1 Env, or the acylation signal motifs of lyn, Ga (12) , Ga (13) and Ga (16) . This makes the original Gag myr signal unable to function. For CD4 and CXCR4, the full-length (FL) and cytoplasmic tail-deleted derivatives (DC) were examined. The membrane protein mutants are expected to traffic to the PM through the vesicular trafficking pathway involving ER and Golgi apparatus. As lyn encodes two overlapping acylation motifs, a myr and palmitoylation (pal) motif, we generated three lyn-derived constructs bearing a myr signal only, a pal signal only, or both signals (denoted myr lyn , pal lyn , myr/pal lyn ). In the lyn myr signal constructs, the position of the myristoyl group is -22 amino acids upstream from the original Gag context (denoted wild type, WT, hereafter). The gag and env sequences were human codon-optimized. The start codon and myr signal of Gag were destroyed by the M1L and G2A mutations to avoid internal translational initiation that could influence the experimental results.
14 The myr signal-defective Gag construct G2A was used as a negative control. PH-gag was used as a positive control that showed enhanced viral production. 14 The Ga(12), Ga(13) and Ga(16) constructs have one, two and three pal attachment sites, respectively. All the constructs were fused to green fluorescent protein (GFP), and expression was verified by western blot and immunoprecipitation analyses (Figure 1b) .
A confocal microscopic analysis revealed that the majority of Gag-GFP was targeted to the PM, but some Gag-GFP was distributed in the cytoplasm with a fine vesicular pattern in 293FT cells (Figure 1c , WT). G2A-GFP showed a homogenous cytoplasmic distribution (Figure 1c ). PH-Gag-GFP showed a distribution pattern similar to the WT (Figure 1c ). These data are consistent with our previous findings. 14 The membrane protein Gag constructs mostly accumulated in the perinuclear region and only some of the protein was targeted to the PM, as verified by flow cytometric analysis using antibodies recognizing the extracellular domain of CD4, CD8 or CXCR4 (exemplified by the CXCR4 FL mutant in Figure 1c , and data not shown). The myr/pal lyn construct showed a phenotype similar to WT with fine vesicular staining close to the nucleus (Figure 1c) . The myr lyn construct showed a PM-targeting phenotype similar to WT (Figure 1c ). The pal lyn construct was distributed evenly in the cytoplasm similar to G2A (Figure 1c) . The Ga constructs were distributed predominantly in the cytoplasm with vesicular staining patterns, and less evidently at the PM (exemplified by the Ga(16) construct in Figure 1c) .
To evaluate the efficiency of virus-like particle (VLP) production, we measured the GFP fluorescence intensity of culture supernatants containing VLP relative to the cell fraction (Figure 1d ). PH-gag showed a significant enhancement of VLP production (229.0%, Figure 1d ) compared with Gag-GFP, and the G2A construct produced almost no VLP, consistent with previous findings. 14 Membrane protein mutants produced little VLP (0.8-41.6% relative to Gag-GFP), presumably because they were inefficiently transported to the PM as evidenced by the confocal microscopy analysis (Figure 1c) . Among the membrane protein mutants, CXCR4
FL -gag-GFP showed the best VLP production efficiency (41.6% relative to Gag-GFP). Interestingly, deleting the cytoplasmic tail of CXCR4 led to a drastic loss of VLP production (0.8% relative to Gag-GFP), suggesting that the cytoplasmic tail of CXCR4 somehow contributes to VLP production. Myr/pal lyn -gag-GFP showed significantly greater VLP production than the WT (229.4%, Po0.05, Student's t-test). Myr lyn -gag-GFP produced slightly more VLP than the WT (131.5%). Pal lyn -gag-GFP showed a weak VLP production ability (14.1%), possibly because the pal signal did not function effectively, or the palmitoyl group did not function as a PM-targeting motif in the given protein context. The Ga(12)-and Ga(13)-gag-GFP constructs, containing one or two pal motifs, respectively, showed 7.0 and 7.3% VLP production efficiencies, compared with the WT. The Ga(16)-gag-GFP construct, containing three pal motifs, was able to produce VLP (28.8%) more effectively than the other Ga constructs, suggesting that the pal group serves as a weak PM-targeting motif and that the motifs function additively. The two-to threefold enhancement of VLP production by PH-and myr/pal lyn -gag-GFP was verified by western blot analysis examining the VLP fraction (data not shown). Overall, the GFP fluorescencebased VLP production assays were consistent with the microscopy observations indicating that the constructs that were able to target Gag to the PM were competent in VLP production ( Figure 1c ). These data indicate that the Gag constructs carrying lyn myr/pal or myr signals support VLP production more efficiently than the WT. Thus, we examined the infectivity of the lentiviral vectors produced by Gag with heterologous myr signals.
We constructed gag-pol derivatives bearing the myr/pal lyn or myr lyn sequences, and additional myr signal constructs carrying the myr signal of HIV-1 or MLV MA (myr HIVÀ1 -or myr MLV -gag-pol, Figure 1a ). These constructs were generated to examine whether any heterologous myr signal can function to enhance VLP production similar to the effect of the lyn acylation signal. In myr HIVÀ1 -or myr MLV -gag-pol, the position of the myristoyl group is -22 amino acids upstream from the original Gag context, which is similar to the same position as myr/pal lyn and myr lyn mutants (Figure 1a ). The expression of the gag-pol derivatives was verified by western blot analysis in which Pr55
Gag and its cleaved products by viral protease including MA-CA and p24 CA were detected (Figure 2a ). These mutants produced VLP in the culture supernatant as verified by western blot analysis (Figure 2b ). Using these gag-pol expression plasmids, in combination with the luciferase-encoding gene transfer plasmid and expression plasmids for Rev and VSV-G, we produced a lentiviral vector in 293FT cells. The viral production efficiencies were assessed by measuring the amount of viral capsid antigen p24 CA Improved lentiviral vector by Gag modification T Aoki et al Figure 1 The production of VLPs by genetic modification of the PM-targeting signal of Gag. (a) The mutants used in this study. The myr site is marked with a dot, the palmitoylation site with an underline. The Gag translational initiation site and the myr target residues were mutated to leucine and alanine to minimize internal translational initiation and myr. (b) The verification of protein expression of Gag-GFP derivatives in 293FT cells by western blot analysis using anti-FLAG antibody. All the constructs carry the FLAG epitope at the C-terminus of Gag. The CXCR4 FL -Gag-GFP showed a low efficiency of detection, thus the immunoprecipitation was performed before immunoblotting (triangle). 
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T Aoki et al in the culture supernatant by enzyme-linked immunosorbent assay (ELISA). Enhancement of virus production by the PH, myr/pal lyn and myr lyn constructs was observed (4.1-, 6.3-and 10.5-fold increase in production, respectively, relative to the WT, Table 1 ). These data are consistent with the western blot analysis in which the levels of p24 CA are decreased from the cell fraction and increased in the VLP fraction for PH and myr signal mutants ( Figure 2a ). The magnitude of viral production enhancement was augmented in the gag-pol context compared with the Gag-GFP context. This is explained by the efficiency of Gag cleavage in the virion as described below. Viral production by the myr HIVÀ1 -or myr MLV -gag-pol constructs also increased (6.2-or 6.1-fold, respectively, Table 1 ), suggesting that any heterologous myr signal can increase the production of lentiviral vector.
Luciferase gene transduction by lentiviral vectors produced using the modified Gag-pol was assessed in 293FT cells. The gene transduction efficiencies of gag-pol constructs were 6.1-to 10.9-fold greater than the WT ( Figure 2b and Table 1 ). The luciferase activity decreased on treatment of the cells with the reverse transcriptase inhibitor nevirapine, suggesting that the luciferase activity indeed represents lentiviral gene transduction (data not shown). The increase in viral production by the heterologous myr signal constructs (4.3-to 7.8-fold compared with WT) largely agrees with the level of augmentation of luciferase activity (5.7-to 10.4-fold, Table 1 ). The myr/pal lyn mutant showed a higher ratio (1.7) of luciferase transduction efficiency relative to viral production than the other myr signal mutants, 
Abbreviations: HIV-1, human immunodeficiency virus type 1; MLV, murine leukemia virus; myr, myristoylation; pal, palmitoylation; PH, pleckstrin homology; WT, wild type. a The average ± s.e.m. of the p24 CA concentration relative to WT from the indicated number of independent experiments. b The average±s.e.m. of transduced luciferase activity relative to WT from the indicated number of independent experiments. c The luciferase transduction divided by viral production. Asterisks indicate a statistically significant difference compared to the WT by two-tailed Student 0 s paired t-test (*Po 0.05, **Po 0.01).
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suggesting that the infectivity of the myr/pal lyn virus particles is slightly improved (Table 1) . Luciferase gene transduction by myr signal constructs was also observed in the B lymphoid cell line BJAB and T lymphoid cell line M8166, similar to 293FT cells (Figure 2b ). Gene transduction of GFP by myr signal gag-pol constructs was comparable to transduction of the luciferase gene (data not shown). Collectively, these results indicate that extending the amino-terminus of Gag with a heterologous myr signal enhances infectious lentiviral production.
We analyzed the molecular mechanisms by which viral production was improved by the amino-terminal Gag modifications. We examined (i) the oligomerization efficiency, (ii) the Vps4-dependence of viral budding, (iii) Gag targeting to the Triton X-100-insoluble lipid (detergent-resistant membrane, DRM) fraction and (iv) the morphology of the virion. First, the oligomerization efficiency was measured using a bioluminescent resonance energy transfer (BRET) assay (Figure 3a) . The 293FT cells were co-transfected with plasmids expressing Gag derivatives fused to GFP or renilla luciferase (Rluc), and the GFP fluorescence activated by the Rluc-emitted light was measured in living cells. This BRET signal should represent the self-oligomerization efficiency of Gag derivatives in vivo. The GFP-Rluc fusion protein should yield the best BRET efficiency, and was thus used as the positive control. Rluc alone should not yield any BRET signal, and thus was used as a negative control. We focused on the derivatives that showed enhanced viral production. The BRET levels of all the tested mutants were significantly increased compared with the WT Gag (Figure 3a) . These data imply that the assembly of the myr signal Gag constructs is more efficient than the WT. It is conceivable that the enhanced VLP production of myr signal Gag constructs is, in part, because of improved assembly efficiency. Efficient Gag assembly should also assist the Gag-pol assembly. The Gag-pol assembly leads to the activation of a viral protease that cleaves Gag to make the virus infectious. Provided that the myr signal Gag mutants can efficiently activate the viral protease, we expected that the Gag processing of myr signal Gag constructs should be more efficient than the WT. Virions were collected by centrifugation and processed for western blotting using the anti-p24 CA monoclonal antibody (mAb). Anti-p24
CA mAb binds to Pr55
Gag and its cleaved products including MA-CA and p24 CA . The p24 CA signal relative to the Pr55 Gag and MA-CA represents the Gag processing efficacy. Compared with cell lysates (Figure 2a ), viral lysates showed better Gag cleavage for all samples (Figure 3b ). The WT virions showed a substantial amount of Gag intermediates (Figure 3b ). In contrast, only trace amounts of intermediate were detected in the myr signal construct virions (Figure 3b ). It is possible that the enhanced Gag processing is due to the increased Gag-pol to Gag ratio in the virion produced by myr Gag mutants. We tested this possibility by western blot analysis probing p24 CA and integrase (IN) at the same time. IN represents the Gag-pol because IN is one of the proteolytic products generated from Gag-pol. The signal intensities of IN (open arrowhead, Figure 3b ) relative to p24 CA (filled arrowhead, Figure 3b ) for myr signal mutants were comparable to WT, suggesting that enhanced Gag processing is not due to the increased Gag-pol to Gag ratio in the virion produced by myr Gag constructs. Collectively, the results suggest that the heterologous myr signals enable Gag to assemble with a higher efficiency, leading to the activation of protease to process Gag more efficiently in the virion. This should account for the fact that the magnitude of difference between WT and mutants in VLP production was assessed greater by p24 ELISA assay using gag-pol constructs than by GFP fluorescencebased assay using Gag-GFP constructs.
Second, the Vps4-dependence of VLP budding was examined. Vps4 drives HIV-1 budding. 15 We measured VLP production efficiencies by gag-pol derivatives in the presence or absence of a dominant-negative Vps4. If VLP budding is powered by a Vsp4-independent mechanism, expression of dominant-negative Vps4 should not reduce the VLP production efficiency. Viral gene expression was 
CA levels ( Figure 4 ). However, on expression of dominant-negative Vps4, viral production decreased in all the mutants (the lower panel of Figure 4 ), suggesting that the amino-terminal modification of Gag does not alter the molecular mechanism of viral budding.
Third, DRM targeting was examined using membrane floatation assays. Gag has previously been shown to form higher order complexes and bud at DRM-containing regions. 16, 17 Increased viral production by myr signal Gag constructs may be due to improved efficiency of DRM targeting. In our experimental conditions, approximately 70% of Gag-GFP distributed to the DRM fractions ( Figure 5 ). In contrast, G2A-GFP distributed predominantly to the non-DRM fractions ( Figure 5 ). These data are consistent with the microscopy observations and previous reports (Figure 1c and Lindwasser and Resh 16 and Ono and Freed 17, 18 ). The myr signal derivatives accumulated in the DRM fractions at levels similar to the WT ( Figure 5 ). These data suggest that enhanced viral production is not due to enhanced DRM targeting of Gag with amino-terminal modifications.
Finally, the morphology of the virion was analyzed using TEM. We compared the morphology of the WT and the myr lyn -gag-pol virions. The morphology of budding and mature virions of myr lyn -gag-pol construct was indistinguishable from the WT (Figure 6 ).
14 In addition, VSV-G was incorporated into the virion produced by myr signal derivatives at levels similar to the WT (data not shown). Similar observation was made for the incorporation of HIV-1 Env onto the virion (data not shown). The myr HIVÀ1 -and myr MLV -Gag-GFP showed a PM-targeting phenotype similar to the WT as judged by confocal microscopy (data not shown). Taken together, lentiviral vectors bearing amino-terminally engineered Gag can produce virions with greater efficiencies than the original lentiviral vector. This increase was primarily attributed to the effects of the increased efficiency Gag oligomerization.
Discussion
In this study, we have provided evidence that genetic modification of the structural protein Gag can improve the virion production efficiency of the HIV-1-based lentiviral vector up to 10-fold. Our technology will provide an improved lentiviral vector for human gene therapy applications, which require large-scale viral vector preparation. Historically, efforts to improve the lentiviral vector have not involved the modification of the structural protein Gag. 9 Our strategy is unique in this regard. Our viral vector can be defined as a next generation lentiviral vector. This approach may also be worth testing for murine leukemia virus (MLV)-based vectors because the function of the MLV Gag is dependent on amino-terminal myr sites, similar to HIV Gag. Figure 4 The effect of dominant-negative Vps4 (DnVps4) on virus production by acylation signal Gag derivatives. DnVps4 expression did not lower Gag expression in transiently transfected 293FT cells. In contrast, the virus production by all the Gag constructs was inhibited by DnVps4, similar to the WT. Figure 5 The targeting of Gag-GFP derivatives to the DRM fraction examined by a membrane floatation assay. G2A construct distributed to the non-DRM fractions (lanes 8-10), and WT Gag was targeted to the DRM (lanes 2-3). Other mutants distributed to the DRM fractions similar to WT Gag. All the derivatives were probed with anti-FLAG antibody. Figure 6 The morphology of virions produced from 293FT cells transiently transfected with gag-pol (WT, left) or myr lyn -gag-pol (right) expression vector. The upper panels show viral budding at the cell periphery, and the lower panels show the morphology of virions found in the extracellular space. The bar represents 100 nm, magnification Â 50 000.
Improved lentiviral vector by Gag modification T Aoki et al
Our genetic approach revealed that amino-terminal modifications that re-position the myristoyl group attachment site on Gag can alter the late phases of the HIV-1 life cycle. Gag traffics to the PM efficiently, and the myristoyl group is critical for this process. 19 The myristoyl group attached to Gag is in equilibrium between exposed and folded 'hidden' conformations. 20 The PM targeting of Gag depends primarily on myristoyl group exposure. It is possible that re-positioning of the myristoyl group on Gag may slightly shift the structural equilibrium toward the exposed conformation, which facilitates PM targeting by Gag. However, myr signal Gag mutants did not show higher DRM-targeting efficiencies than WT ( Figure 5 ). We performed the membrane floatation assay without Triton X-100 and found that the myr signal Gag mutants and WT distributed to the membrane fraction at similar efficiencies (data not shown). These data may suggest that the myristoyl group exposure model is unlikely. However, these data may not necessarily negate the myristoyl group exposure model because it is possible that the steady-state levels of Gag association with DRM could be saturable. Alternative hypothesis is that the re-positioning of myristoyl group may stabilize the Gag-PM association or Gag-Gag interaction, both of which should lead to an increased viral production.
Membrane proteins do not serve as an ideal PMtargeting motif for improvement of the lentiviral vector. The substitution of myr signal with membrane proteins appears to be less favorable because the PM-targeting efficiency of the membrane protein constructs was not high enough to produce VLP, probably because Gag starts to assemble on the ER membrane and bud into intracellular membrane compartments. This premature assembly may block the efficient ER exit of the membrane protein-Gag derivatives. In 293FT cells transiently transfected with plasmids expressing membrane Gag mutants, high electron density signals on the intracellular membranes and PM, representing assembled membrane protein-Gag mutants, were observed (data not shown). In addition, intracellular VLP formation was observed in intracellular membrane compartments surrounding the nucleus (data not shown). These observations were consistent with the confocal microscopy data, and suggest that the membrane protein-Gag constructs are assembly-competent. Interestingly, the morphology of the intracellular virion of CXCR4 DC -gag-pol was similar to late domain-defective HIV-1 particles. These data may imply that the membrane protein-Gag derivatives are not fully competent in VLP formation and/or release.
Considering our data, HIV-1 could have evolved to be able to produce more virus particles than it does now. However, such a virus was not selected in nature. This is presumably because the increased viral production may not confer a strong selective advantage for HIV-1 to spread in human population. It is possible that such a virus may kill the host, resulting in the loss of opportunity to be transmitted to a new host. Alternatively, such a virus may be more immunogenic, thus have selective disadvantage in the host. Conversely, it is possible that HIV-1 has already evolved to bud from its natural target cells, namely CD4-positive T lymphocytes or macrophages. If this is the case, our experimental observation might be only applied to the lentiviral vector production in 293FT cells.
Our next generation lentiviral vector should contribute to an increase in lentiviral vector applications, as a tool both for molecular biology research and for human gene therapy. The safety concerns involving Gag aminoterminal modification should be critically examined to use the modified lentiviral vector in clinical trials because the effect of amino-terminal modification of Gag on the lentiviral life cycle is unpredictable. The aminoterminal modification of Gag may alter the chromosomal integration site preference of the lentiviral vector genome. A genome-wide survey to determine the cellular genomic loci in which the Gag-modified lentiviral vector preferentially inserts its genome, compared with the original viral vector, should be conducted. In addition, it may be important to measure the frequency of insertional oncogenesis using small animal models. It is also possible that the fidelity of reverse transcription could be affected by the Gag aminoterminal modification. If the accuracy of reverse transcription drops, the therapeutic effect of the modified lentiviral vector might be affected. These issues should be addressed before the modified lentiviral vector is applied to human gene therapy.
We may be able to further improve the lentiviral vector using systematic modifications of Gag, but such an approach has yet to be examined. For example, the positioning the myr attachment site in all the myr signal Gag derivatives tested in this study was -22 amino acids relative to the original position. A better myristol grouppositioning site or other PM-targeting signals to boost viral production and infectivity could be identified by performing an exhaustive systematic modification study.
Materials and methods

Plasmids
The codon optimized HIV-1 gag was amplified by PCR from pSyn HIV-1 gag-pol 21 using the following primers: HIV-1 gag forward 5 0 -ACCGGTCTCGAGCCACCAT GGGCGCCAGGGCCAGCGTGCTGAGC-3 0 , HIV-1 gag reverse 5 0 -TCATTGGATCCGGTCGTCATCGTCTTTGT AGTCTTGTGACGAGGGGTCGTTGCCAAAG-3 0 . The PCR fragment was cloned into pCR4 Blunt TOPO (Invitrogen, Tokyo, Japan), digested with XhoI-BamHI, and the resulting fragment was cloned into the XhoIBamHI sites of pEGFP-N2 (Clontech, Palo Alto, CA, USA), generating pGag-GFP. A FLAG epitope tag was encoded at the carboxy-terminus of Gag. The LA-gag has been described previously.
14 The SnaBI-SacII fragment from pLA-gag-pol was cloned into the SnaBI-SacI sites of pSyn HIV-1 gag-pol, generating the pLA-gag-GFP.
The CD4 FL or DC was amplified from CD4 complementary DNA 22 using the following primers: FL and DC forward 5 0 -GGATCCCGGGCCACCATGAACCG GGGAGTCCCTTTTAGGC-3 0 , FL reverse 5 0 -GAATT CAATGGGGCTACATGTCTTCTGAAACCGG-3 0 , and DC reverse 5 0 -GAATTCGTGCCGGCACCTGACACAGAAG AAGATGCC-3 0 . The PCR fragments were cloned into pCR4 Blunt TOPO (Invitrogen), digested with BamHIEcoRI, and the resulting fragments were cloned into the BglIIEcoRI sites of pEGFP-N2, generating pCD4 FL/DC -GFP. The SnaBI-EcoRI fragments from pCD4 FL/DC -GFP were cloned into the corresponding sites of pLA-gag-GFP, generating pCD4 FL/DC -gag-GFP.
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The full-length human CD8 ORF was amplified by reverse transcriptase-PCR using mRNA isolated from peripheral blood mononuclear cell (PBMC) with following primers: 5 0 -GCTAGCATGGCCTTACCAGTGAC-3 0 and 5 0 -AGATCTATGACGTATCTCGCCGAAAGGCT-G-3
0 . An NheI-BglII fragment was cloned into the corresponding sites of pEGFP-N1 (Clontech), generating pEGFPN1hCD8. The SnaBI-SalI fragment from pEGFPN1hCD8 was cloned into the SnaBI-XhoI site of pCXCR4 FL -gag-GFP, generating pCD8-gag-GFP. The CXCR4 FL and DC were amplified from the CXCR4 complementary DNA 22 using the following primers: FL and DC forward 5 0 -ACCGGTGCCACCATG GAGGGGATCAGTATATACACTTCAG-3 0 , FL reverse 5 0 -AGATCTCGCTGGAGTGAAAACTTGAAGACTCAGA CTC-3 0 , and DC reverse 5 0 -AGATCTTGGCTCCAAG GAAAGCATAGAGGATGGG-3 0 . The AgeI-BglII fragments of the PCR products were cloned into AgeI-BglII sites of pEGFP-C2, generating pCXCR4 FL/DC -GFP. The SnaBI-EcoRI fragments from pCXCR4 FL/DC -GFP were cloned into the corresponding sites of pLA-gag-GFP, generating pCXCR4 FL/DC -gag-GFP. The following oligonucleotides were annealed and cloned into the BsrGI site of pEGFP-N2 to generate pEGFP-N2-FLAG: 5 0 -GTACGACTACAAAGACGATGA CGACTATAAGTAAGC-3 0 and 5 0 -GGCCGCTTACTTA TAGTCGTCATCGTCTTTGTAGTC-3 0 . HIV-1 Env was amplified from pgp160opt that encodes a codon-optimized gp160 (obtained through the NIH AIDS Research and Reference Reagent Program 23 ) using the following primers: 5 0 -GGAACTGGTTCGACATCACCAAGTGGCT GTGG-3 0 and 5 0 -GTTAACCCCGGGATCCAGCAGGGC GGTCTCGAAGCCCTGGCGGATGCGGC-3 0 . The BglIIXmaI fragment of the PCR product was cloned into pEGFP-N2 flag, generating pgp160opt3fwd2revEGFPN2f. The NdeI-SfiI fragment from pgp160opt was cloned into pgp160opt3fwd2revEGFPN2f, generating pgp160optGFPf. The AfeI-MfeI fragment carrying gag-GFP was cloned into the pgp160optGFPf, generating pEnv-gag-GFP.
The PH domain of phospholipase C-d1 from pGFP-PH (generous gift from Dr Meyer's group, 24 ) was amplified using following primers: forward 5 0 -CGCTAGCACC GGTGCCACCATGGACTCGGGCCGGGACTTCCTG-3 0 and reverse 5 0 -CCTCGAGGCTGGATGTTGAGCTCCTT CAGG-3 0 . The NheI-XhoI fragment of the PCR product was cloned into the corresponding sites of pLA-gag-GFP, generating pPH-gag-GFP.
The following oligonucleotides were annealed and inserted into the NheI-XhoI sites of pLA-gag-GFP to generate pmyr/pal lyn -gag-GFP, pmyr lyn -gag-GFP, ppal lyngag-GFP, pGa (12)-gag-GFP, pGa (13) Other plasmids including pLenti-luciferase, pVSV-G and pRevpac have been described previously. 14 
Cells and transfection
Cells were maintained in RPMI 1640 medium (Sigma, St Louis, MA, USA) supplemented with 10% fetal bovine serum (Japan Bioserum, Tokyo, Japan), 50 U ml -1 penicillin and 50 mg ml -1 streptomycin (Invitrogen), at 37 1C in a humidified 5% CO 2 atmosphere. Cells were 
Western blotting
Transfected 293FT cells were washed once with Dullbeco's phosphate-buffered saline (Sigma), centrifuged and lysed in a buffer containing 0.31 M Tris-HCl (pH 6.8), 10% (w/v) sodium dodecyl sulfate, 50% (v/v) glycerol, 500 mM dithiothreitol and 0.25% (w/v) bromophenol blue. Proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to polyvinylidine difluoride membranes (Millipore, Tokyo, Japan). Membranes were incubated with primary antibodies including polyclonal anti-flag (Rockland Immunochemicals, Gilbertsville, PA, USA), anti-p24 CA mAb clone 183-H12-5C (NIH AIDS Research and Reference Reagent Program), anti-HIV-1 IN mAb clone ab72007 (Abcam, Cambridge, MA, USA) or antiBip mAb clone 40 (BD Biosciences, Tokyo, Japan), followed by a horseradish peroxidase conjugated secondary antibody (Envision, Dako, Tokyo, Japan). Chemiluminescence was generated using Lumilight (Roche, Tokyo, Japan) or Lumigen (GE Healthcare, Tokyo, Japan). Signals were detected using an LAS-3000 mini Lumino-Image analyzer operated by the LAS-300 mini Image Reader software (ver.2.2, Fuji Film, Tokyo, Japan). The brightness and contrast of the image were adjusted using Adobe Photoshop (ver.7.0, Adobe, Tokyo, Japan).
Confocal microscopy
Transfected 293FT cells were grown on slide glass in the presence of Hoechst 33258 (Sigma) for 24 h, fixed (4% formaldehyde), mounted and analyzed using confocal fluorescence microscopy (LSM510 Meta 63 Â NA 1.4 lens, Carl Zeiss MicroImaging Inc., Tokyo, Japan). The brightness and contrast of the image were adjusted using the LSM image browser (Carl Zeiss).
VLP assay
Transfected 293FT cells were washed once with phosphate-buffered saline, centrifuged and lysed in buffer A (150 mM NaCl, 50 mM Tris-HCL (pH 8.0), 0.5% IGEPAL CA-630) for 0.5-1 h on ice (cell fraction). The cell culture medium was collected, passed through a 0.45 mm filter, and VLP were pelleted by ultracentrifugation (541 k Â g for 1 h). The VLP pellet was lysed in buffer A for 0.5-1 h (VLP fraction). The green fluorescent intensities of cell and VLP fractions were quantified with a DTX880 Multimode Detector (excitation 485 nm, emission 535 nm) (Beckman Coulter, Tokyo, Japan). The efficiency of VLP production was calculated by dividing the green fluorescent intensity of the VLP fraction by that of the cell fraction.
Infection with lentiviral vector
The 293FT cells grown in six-well plates were transfected with gag-pol vector (1 mg), pLenti-luciferase (0.65 mg), pVSV-G (0.4-0.8 mg) or pRevpac (0.05 mg) using Lipoftamine 2000, and replated into three wells of a six-well plate at 4-6 h after transfection. At 48 h after transfection, the cell culture medium was collected, passed through a 0.45 mm filter (Millex-HV polyvinylidine difluoride; Millipore), and mixed with dextran (final concentration 16.25 mg ml -1
; DEAE-Dextran chloride, MW B500 kDa; ICN Biomedicals Inc., Aurora, OH, USA). The 293FT cells at 50% confluency in 24-well plates were exposed to 800 ml of cell culture medium containing viruses. At 4-6 h after infection, 293FT cells were split into 4 wells of a 48-well plate. At 48 h after infection, the luciferase activity was measured using the Steady-Glo Luciferase Assay system (Promega). Luminescence was detected using a Veritas Microplate Luminometer (Promega).
Enzyme-linked immunosorbent assay
A p24 ELISA was conducted according to the manufacturer's protocol (Zeptometrics, Buffalo, NY, USA). To measure cellular p24, transfected 293FT cells were washed once with phosphate-buffered saline, lysed in 500 ml buffer A (described above) for 30 min, and subjected to the ELISA.
Bioluminescence resonance energy transfer
The basic protocol for the BRET assay has been described previously. 25 Briefly, 293FT cells grown in a six-well plate were transfected with 0.05-0.2 mg of expression plasmids for Gag derivatives fused to the Rluc together with 1-2 mg of Gag derivatives fused to GFP. At 48 h after transfection, cells were collected and incubated with the Rluc substrate according to the manufacturer's protocol, with the exception that a 5-to 10-fold higher substrate concentration was used (ViviRen Live Cell Substrate; Promega). We measured BRET signals under the conditions in which the GFP and Rluc expression levels were almost similar among the tested samples. The fluorescent and bioluminescent signals were measured using a Tristar LB941 instrument (Berthold Technologies, Bad Wildbad, Germany).
Membrane floatation assay
293FT cells were transfected with a gag expression vector using Lipofectamine 2000 (Invitrogen) according to the manufacturer's protocol. At 48 h after transfection, cells were rinsed with ice-cold phosphate-buffered saline and centrifuged at 600 Â g for 5 min. Cell pellets were resuspended in a buffer containing 10 mM Tris-Cl (pH 7.5), 4 mM EDTA and protease inhibitor cocktail (Sigma), and sonicated on ice. Cell lysates were centrifuged at 370 Â g for 3 min. A 120 ml aliquot of supernatant was mixed with 3.6 ml 5 M NaCl (final concentration ¼ 150 mM) and 120 ml of TNE-T (100 mM Tris-Cl (pH 7.5), 600 mM NaCl, 16 mM EDTA and 0.5% Triton X-100). These samples were placed on ice for 20 min. Subsequently, 200 ml of supernatant was mixed with 1 ml of 85.5% (wt/vol) sucrose in TNE and placed on the bottom of a centrifuge tube (Ultra Clear, Beckman Coulter), overlayed with 2.8 ml 65% and 1.2 ml 10% (wt/vol) sucrose in TNE-T without Triton X-100 (TNE), respectively. The gradient solution was centrifuged for 16 h at 1 48 862 Â g at 4 1C in a BECKMAN SW55Ti rotor and 10 fractions of 500 ml each were recovered from top-to-bottom.
Transmission electron microscopy (TEM)
Transmission electron microscopy imaging was conducted by Hanaichi Co Ltd (Okazaki, Japan). Transfected 293FT cells were removed culture medium, fixed (2% glutaraldehyde, 2% osmium tetroxide), and imaged by transmission electron microscopy (at 100 kV; Improved lentiviral vector by Gag modification T Aoki et al
